N/A
N=30
Acupuncture Therapy for COVID-Related Olfactory Loss
Olfactory Dysfunction · COVID-19
Bottom Line
View on ClinicalTrials.gov: NCT04952389 ↗Enrolled (actual)
30
Serious AEs
0.0%
Results posted
Mar 2024
Primary outcome: Primary: Change in University of Pennsylvania Smell Identification Test (UPSIT) Scores — 2.571; 3.182 score on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Acupuncture Therapy (Device); Budesonide (Drug); Olfactory Training (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Mayo Clinic
- Primary completion
- Apr 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in University of Pennsylvania Smell Identification Test (UPSIT) Scores |
2.571; 3.182 | — |
| SECONDARY Change in Patient-reported Subjective Olfactory Loss |
1.857; 1.727 | — |
| SECONDARY Change in Sino-Nasal Outcome Test (SNOT-22) |
7.143; 3.455 | — |
Summary
This study is looking at the role of acupuncture as a treatment for olfactory dysfunction in patients who tested positive for COVID-19.
Eligibility Criteria
Inclusion Criteria
- 18 years or older.
- Patients with post-viral olfactory dysfunction > 4 weeks.
- History of positive COVID-19 PCR.
Exclusion Criteria
- Less than 18 years of age.
- Active sinus infection.
- New diagnosis of untreated CRS.
- Prior diagnosis of dementia or Parkinson's disease.
- Prior head trauma or neurosurgical procedure resulting in olfactory loss.
- Patients who do not speak or read English.
- Patients unable to understand and sign the study consent.
Data sourced from ClinicalTrials.gov (NCT04952389). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.